![Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing](https://cdn.cancerletter.com/media/2022/04/29132656/48-17-MTD-4x3-1.jpg)
![Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing](https://cdn.cancerletter.com/media/2022/04/29132656/48-17-MTD-4x3-1.jpg)
Cover Story
Clinical
By Alice Tracey
For decades, pinpointing the highest dose of a drug that cancer patients could tolerate was the first step investigators were required to take before moving into phase II and III clinical trials.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Proposed rule by CMS would expand access to cancer treatment at tribal facilities
- A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital
- Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”